Blueshift Asset Management’s Arcus Biosciences RCUS Stock Holding History

Blueshift Asset Management’s Portfolio RCUS Stock Details RCUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-8,327	Closed	-$263K	–	953
2022 Q1	$263K	Buy	+8,327	New	+$279K	0.02%	659
2021 Q4	–	Sell	-11,816	Closed	-$412K	–	1164
2021 Q3	$412K	Sell	11,816 -13,287	-53%	-$414K	0.02%	702
2021 Q2	$689K	Buy	+25,103	New	+$717K	0.04%	456
2020 Q4	–	Sell	-19,491	Closed	-$334K	–	844
2020 Q3	$334K	Sell	19,491 -6,932	-26%	-$155K	0.05%	423
2020 Q2	$654K	Buy	+26,423	New	+$713K	0.11%	270

Other funds holding RCUS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

IFA

Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Blueshift Asset Management's RCUS Position: Q2 2022 in Review

Blueshift Asset Management sold out of Arcus Biosciences (RCUS) in Q2 2022, closing a stake of 8,327 shares — an estimated $263K sold.

Blueshift Asset Management first reported a position in RCUS in Q2 2020 and held it in 5 quarters. The position peaked at $689K in Q2 2021. 173 funds tracked by Wall St. Rank hold RCUS as of Q2 2022.

Blueshift Asset Management reported no remaining Arcus Biosciences position as of Q2 2022 after selling out during the quarter.
Blueshift Asset Management sold 8,327 Arcus Biosciences shares in Q2 2022, an estimated $263K.
Blueshift Asset Management first reported a position in Arcus Biosciences in Q2 2020 and held it in 5 quarters.
Blueshift Asset Management's Arcus Biosciences position peaked at $689K in Q2 2021.
173 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2022.

Based on Blueshift Asset Management's 13F filing for Q2 2022, filed 12 Aug 2022.